FHA
CLDX icon

Flagship Harbor Advisors’s Celldex Therapeutics CLDX Stock Holding History

Flagship Harbor Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1
Closed – – 748
2020
Q3 		$0 Hold
1
– – ﹤0.01% 1943
2020
Q2 		$0 Hold
1
– – ﹤0.01% 2029
2020
Q1 		$0 Hold
1
– – ﹤0.01% 1880
2019
Q4 		$0 Hold
1
– – ﹤0.01% 1887
2019
Q3 		$0 Hold
1
– – ﹤0.01% 1852
2019
Q2 		$0 Hold
1
– – ﹤0.01% 1870
2019
Q1 		$0 Hold
1
– – ﹤0.01% 1850
2018
Q4 		$0 Hold
1
– – ﹤0.01% 1872
2018
Q3 		$0 Hold
1
– – ﹤0.01% 2075
2018
Q2 		$0 Buy
+1
New +$13 ﹤0.01% 2027

Other funds holding CLDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Flagship Harbor Advisors's CLDX Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2020, closing a stake of 1 share.

Flagship Harbor Advisors first reported a position in CLDX in Q2 2018 and held it in 10 quarters. The position peaked at $0 in Q3 2020. 130 funds tracked by Wall St. Rank hold CLDX as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Celldex Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 1 Celldex Therapeutics share in Q4 2020.
  • Flagship Harbor Advisors first reported a position in Celldex Therapeutics in Q2 2018 and held it in 10 quarters.
  • Flagship Harbor Advisors's Celldex Therapeutics position peaked at $0 in Q3 2020.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.